A novel PET neuroimaging tracer detects abnormal inflammation in the cerebral gray matter of patients with secondary progressive multiple sclerosis.
Injecting extracellular vesicles from healthy mice into mice that had an MS-like disease resulted in the development of a relapse-remitting disease and active CD8+ cells, similar to that seen in human patients with multiple sclerosis. Examining the EVs in mice and humans with MS, researchers identified they contained fibrinogen, a protein normally associated with blood clotting and wound healing. According to researchers, the EVs with fibrinogen appear to activate the CD8+ immune cells. The findings could help with the development of new treatments for RRMS.
Researchers reveal that a year after receiving autologous haematopoietic stem cell transplantation for relapse remitting multiple sclerosis, almost all of the patients showed no signs of the disease and the level of their disability was significantly improved.
A new Nature Communications study reports the antidepressant Clomipramine may relieve symptoms of primary progressive multiple sclerosis.
Researchers report resistance training may slow down the progression of multiple sclerosis by protecting the nervous system against the disease.
Clinical trials show that a new drug called ocrelizumab can reduce attacks in people with RRMS, and can reduce new symptom development in patients with primary progressive multiple sclerosis.
